Fortrea sees obesity drug development shifting toward long-term health outcomes in 2027
FTRE•Obesity drug development is expected to prioritize sustained weight loss and long-term health outcomes in 2027, with trials increasingly assessing body composition and physical function.
1. Focus on durable benefits
Obesity drug sponsors may face growing expectations to demonstrate durable benefits, with trials increasingly assessing body composition and physical function. Pipeline diversification beyond traditional incretins and oral therapies could create opportunities for personalized treatments and improve convenience and access.
